# NeuroOne Promotes Emily Johns to Chief Administrative Officer

EDEN PRAIRIE, MINN. - October 16, 2025 (NEWMEDIAWIRE) - NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the promotion of Emily Johns to the expanded role of Chief Administrative Officer (CAO) and General Counsel. Johns, who joined NeuroOne earlier this year as its General Counsel, will continue to lead the legal strategy for NeuroOne. Additionally, she will now oversee all human resources, compliance, security and risk areas of the organization.

 Dave Rosa, President and CEO of NeuroOne, said, “In the short time that Emily has been with NeuroOne she has made impactful contributions to the organization and the future growth of the business. We look forward to her future contributions as we continue to scale our business.”

 “I am honored to step into this role and continue building on the strong foundation our exceptional team has created,” Johns said. “As we look ahead, I look forward to strengthening our operations and infrastructure to help bring our life-changing technologies to more people.”

 Ms. Johns is an experienced public company lawyer who most recently served as a partner at Honigman LLP, where she represented many companies in the life sciences industry, including representing NeuroOne on all transactional work since 2017. Previously, she began her career at Sullivan & Cromwell LLP, where she represented public companies in securities offerings and M&A transactions. She received her J.D. from UCLA School of Law and her bachelor's degree from the University of Michigan.

 About NeuroOne

 NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit www.nmtc1.com.

 Forward Looking Statements

 This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “forecasts,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue, “focused on,” “committed to” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the strengthening of our operations and infrastructure to help bring our life-changing technologies to more people, and other financial and operating information. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations for the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks related to whether the Company will continue to maintain compliance with all Nasdaq continued listing requirements, risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor shortages or otherwise; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company’s capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks relate to clinical trial patient enrollment and the results of clinical trials; that we may be unable to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.

 IR Contact

 MZ Group – MZ North AmericaNMTC@mzgroup.us

View the original release on www.newmediawire.com 

---

[Original/Source Press Release](https://www.newmediawire.com/news/neuroone-promotes-emily-johns-to-chief-administrative-officer-7083422)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/neuroone-promotes-emily-johns-to-chief-administrative-officer-role/1c5289a48b11db1b663968134ab08bdf) 

 

 



![Blockchain Registration](https://cdn.newsramp.app/newmediawire/qrcode/2510/16/quizYyMQ.webp)